Beneficial changes in microbial composition and functionality with capsular fecal microbiota transplant lead to improved cognition in patients with cirrhosis and recurrent hepatic encephalopathy, according to study data presented at The American Association for the Study of Liver Diseases’ The Liver Meeting 2019, held November 8 to 12 in Boston, Massachusetts. In order to determine…
While ivermectin plus albendazole was not superior in the treatment of onchocerciasis compared with ivermectin alone, semiannual treatment with or without albendazole was superior to annual treatment for suppressing microfilaria in the skin.
The FDA’s Antimicrobial Drugs Advisory Committee voted in favor of pretomanid, as part of a combination regimen with bedaquiline and linezolid, for the treatment of pulmonary extensively drug resistant, treatment intolerant, or nonresponsive multidrug resistant tuberculosis.
Contepo, an investigational epoxide intravenous (IV) antibiotic, has broad spectrum activity against Gram-negative and Gram-positive pathogens, including multi-drug resistant strains such as ESBL-producing Enterobacteriaceae.
Ampicillin plus ceftriaxone was an effective treatment for penicillin-susceptible Enterococcus faecalis infective endocarditis compared with ampicillin plus gentamicin.
Treating outpatients with continuous infusions of flucloxacillin, cefepime, vancomycin, and piperacillin/tazobactam using elastomeric pumps was effective and safe.
Zemdri carries a Boxed Warning describing reports of nephrotoxicity, ototoxicity, and neuromuscular blockade, as well as fetal harm if administered during pregnancy.
The approval was supported by findings from 12 clinical trials of TPOXX with more than 700 healthy volunteers that showed no drug-related serious adverse events.
Pitavastatin reduced low-density lipoprotein cholesterol to a greater extent than pravastatin with a similar safety profile in patients with HIV and dyslipidemia.
Combining emtricitabine and tenofovir alafenamide (Gilead Sciences) and rilpivirine (Janssen Sciences), Odefsey is Gilead’s second tenofovir alafenamide-based regimen to receive FDA approval.
The Food and Drug Administration (FDA) has approved label changes for simeprevir; (Olysio, Janssen) to include dosing recommendations for the treatment of hepatitis C virus (HCV)/HIV-1 co-infection.
Gilead announced that phase 3 study evaluating its investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (F/TAF) for the treatment of HIV-1 infection met its primary objective.